A systematic review of p53 as a biomarker of survival in patients with osteosarcoma

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3817-3821

  Fu, Hai Liang ^a   Shao, Lin ^a   Wang, Qiang ^a   Jia, Tao ^a   Li, Ming ^a   Yang, Da Ping ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Osteosarcoma; p53; Survival; Systematic review

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SYSTEMATIC REVIEW; UPREGULATION;

EID: 84891483482     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0966-x     Document Type: Article

References (30)

1. Bielack S, Carrle D, Casali PG. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:137-9.
2. Grimer RJ. Surgical options for children with osteosarcoma. Lancet Oncol. 2005;6:85-92.
3. Akiyama T, Dass CR, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther. 2008;7:3461-9.
4. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28:247-63.
5. Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670-8.
6. Ye ZM, Li WX, Fan SW, Yang DS, Tao HM. Expression of p53 protein and proliferating cell nuclear antigen (PCNA) in osteosarcoma and its prognostic significance [article in Chinese]. Zhejiang Med J. 2000;22:65-7.
7. Zhang L, Yang ZY, Tang RY, Mei J, Ai ZS. The relationship with the protein expression of p53, pten and the three-year survival ratios in osteosarcoma patients [article in Chinese]. J Pract Radiol. 2003;19:673-6.
8. Wu X, Chen ZR, Zhang GJ. [Apoptosis-related gene expression and its clinical significance of human osteosarcoma]. Zhonghua Zhong Liu Za Zhi. 2004;26:678-81.
9. Bao Y, Li HP, Fan R, Jiang C. Expression of p53 protein in osteosarcoma and its significance [article in Chinese]. Acta Acad Med CPAPF. 2006;15:230-1.
10. Hu X, Yu AX, Qi BW, Fu T, Wu G, Zhou M, et al. The expression and significance of idh1 and p53 in osteosarcoma. J Exp Clin Cancer Res. 2010;29:43.
11. Zhang SQ, Xiao DM, Zhu YH, Guan H, Li W, Tan JF. Protein expression of p53 in osteosarcoma and the correlation with clinical features and prognosis [article in Chinese]. J Mod Oncol. 2011;19:145-6.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-48.
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
16. Boulytcheva IV, Soloviev YN, Kushlinskii NE, Mahson AN. Expression of molecular markers in the tumor and survival prognosis in osteosarcoma. Bull Exp Biol Med. 2010;150:237-42.
17. Ferrari S, Bertoni F, Zanella L, Setola E, Bacchini P, Alberghini M, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100:1936-42.
18. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781-8.
19. Kaseta MK, Khaldi L, Gomatos IP, Tzagarakis GP, Alevizos L, Leandros E, et al. Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma. J Surg Oncol. 2008;97:259-66.
20. Oliveira CR, Mendonca BB, Camargo OP, Pinto EM, Nascimento SA, Latorre Mdo R, et al. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters. Clinics (Sao Paulo). 2007;62:167-74.
21. Ozger H, Eralp L, Atalar AC, Toker B, Esberk Ates L, Sungur M, et al. [The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis]. Acta Orthop Traumatol Turc. 2009;43:28-34.
22. Papai Z, Feja CN, Hanna EN, Sztan M, Olah E, Szendroi M. P53 overexpression as an indicator of overall survival and response to treatment in osteosarcomas. Pathol Oncol Res. 1997;3:15-9.
23. Uozaki H, Ishida T, Kakiuchi C, Horiuchi H, Gotoh T, Iijima T, et al. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract. 2000;196:665-73.
24. Wu X, Cai ZD, Lou LM, Zhu YB. Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiol. 2012;36:212-6.
25. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 2009;9:714-23.
26. Vousden KH, Ryan KM. P53 and metabolism. Nat Rev Cancer. 2009;9:691-700.
27. Silva JL, Vieira TC, Gomes MP, Bom AP, Lima LM, Freitas MS, et al. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins. Acc Chem Res. 2010;43:271-9.
28. Fan C, Lin X, Wang E. Clinicopathological significance of cathepsin d expression in non-small cell lung cancer is conditional on apoptosis-associated protein phenotype: an immunohistochemistry study. Tumour Biol. 2012;33:1045-52.
29. Liu J, Ma Q, Zhang M, Wang X, Zhang D, Li W, et al. Alterations of tp53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur J Cancer. 2012;48:2328-38.
30. Scoccianti C, Vesin A, Martel G, Olivier M, Brambilla E, Timsit JF, et al. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Eur Respir J. 2012;40:177-84.